{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(1)"],"submitter":["Abd Elrahman M"],"pubmed_abstract":["Objectives
In this study, we investigated the association between the IFN-λ3 rs12979860 single nucleotide polymorphism (SNP) and the transition from late fibrosis to HCC in Egyptian HCV-chronically infected patients.Methods
The rs12979860 SNP was genotyped using real-time PCR in DNA from the whole blood of healthy subjects (n=60) and HCV patient s (n=342). We stratified the patients into (1) treatment-naïve patients (n=218) with advanced fibrosis (F2-F4, n=123) and HCC (n=95 Treatment-experienced patients (n=124) who received SOF-based therapy for 12 weeks and achieved SVR (SVR12). DAA-treated patients were divided into 2 groups: group I (n=63) included patients with advanced hepatic fibrosis (F2-F4) who did not develop HCC within a year after treatment, and group II (n="],"journal":["Asian Pacific journal of cancer prevention : APJCP"],"pagination":["215-221"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10152876"],"repository":["biostudies-literature"],"pubmed_title":["The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naive and Experienced."],"pmcid":["PMC10152876"],"pubmed_authors":["Zayed N","Elbatae H","Abd Elrahman M","Tawefeek S","Bader El Din NG","Yosry A","Barakat AZ","Ibrahim MK","Khairy A"],"additional_accession":[]},"is_claimable":false,"name":"The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naive and Experienced.","description":"Objectives
In this study, we investigated the association between the IFN-λ3 rs12979860 single nucleotide polymorphism (SNP) and the transition from late fibrosis to HCC in Egyptian HCV-chronically infected patients.Methods
The rs12979860 SNP was genotyped using real-time PCR in DNA from the whole blood of healthy subjects (n=60) and HCV patient s (n=342). We stratified the patients into (1) treatment-naïve patients (n=218) with advanced fibrosis (F2-F4, n=123) and HCC (n=95 Treatment-experienced patients (n=124) who received SOF-based therapy for 12 weeks and achieved SVR (SVR12). DAA-treated patients were divided into 2 groups: group I (n=63) included patients with advanced hepatic fibrosis (F2-F4) who did not develop HCC within a year after treatment, and group II (n=","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T10:19:13.894Z","creation":"2025-02-19T00:11:50.407Z"},"accession":"S-EPMC10152876","cross_references":{"pubmed":["36708570"],"doi":["10.31557/APJCP.2023.24.1.215"]}}